9 analysts have expressed a variety of opinions on Edwards Lifesciences EW over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 4 | 2 | 0 | 0 |
| Last 30D | 0 | 0 | 0 | 0 | 0 |
| 1M Ago | 1 | 2 | 1 | 0 | 0 |
| 2M Ago | 0 | 2 | 0 | 0 | 0 |
| 3M Ago | 2 | 0 | 1 | 0 | 0 |
Analysts have set 12-month price targets for Edwards Lifesciences, revealing an average target of $87.0, a high estimate of $95.00, and a low estimate of $77.00. This upward trend is apparent, with the current average reflecting a 10.29% increase from the previous average price target of $78.88.
Decoding Analyst Ratings: A Detailed Look
The standing of Edwards Lifesciences among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Rick Wise | Stifel | Raises | Hold | $83.00 | $70.00 |
| Patrick Wood | Morgan Stanley | Raises | Overweight | $95.00 | $80.00 |
| Shagun Singh | RBC Capital | Raises | Outperform | $95.00 | $82.00 |
| Anthony Petrone | Mizuho | Raises | Buy | $95.00 | $85.00 |
| Larry Biegelsen | Wells Fargo | Announces | Overweight | $94.00 | - |
| Shagun Singh | RBC Capital | Raises | Outperform | $82.00 | $80.00 |
| Vijay Kumar | Evercore ISI Group | Lowers | In-Line | $77.00 | $80.00 |
| Richard Newitter | Truist Securities | Raises | Buy | $84.00 | $78.00 |
| Richard Newitter | Truist Securities | Raises | Buy | $78.00 | $76.00 |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Edwards Lifesciences. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Edwards Lifesciences compared to the broader market.
- Price Targets: Gaining insights, analysts provide estimates for the future value of Edwards Lifesciences's stock. This comparison reveals trends in analysts' expectations over time.
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Edwards Lifesciences's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
Stay up to date on Edwards Lifesciences analyst ratings.
Get to Know Edwards Lifesciences Better
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter valve technologies, surgical clips, catheters, and monitoring systems used to measure a patient's heart function during surgery. The firm derives about 55% of its total sales from outside the U.S.
Edwards Lifesciences: A Financial Overview
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Edwards Lifesciences's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2023, the company achieved a revenue growth rate of approximately 13.78%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Edwards Lifesciences's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 24.11% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 5.56%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Edwards Lifesciences's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 3.95%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.1, Edwards Lifesciences adopts a prudent financial strategy, indicating a balanced approach to debt management.
How Are Analyst Ratings Determined?
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
